Poxvirus Vectors Encoding HIV Antigens, and Methods of Use Thereof
AssigneesJanssen Vaccines & Prevention B.V., Bavarian Nordic A/S
InventorsFrank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Life of this patent
Estimating the term…
Abstract
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine combinations containing the disclosed poxvirus vectors, adenovirus vectors encoding one or more HIV antigens, and one or more isolated HIV antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV.
Claims20
A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject in need thereof, the method comprising:
- administering a first vaccine comprising an immunogenically effective amount of one or more recombinant adenovirus vectors, encoding one or more HIV antigens comprising an amino acid sequence of any one or more of SEQ ID NOs:
- 1-5, 18, 28, and 29, and a carrier;
- (ii) administering a second vaccine comprising a poxvirus vector comprising nucleic acid encoding:
- (a) a first HIV envelope (Env) antigen comprising the amino acid sequence of SEQ ID NO:
- 18;
- (b) a second HIV Env antigen different from the first HIV Env antigen;
- (c) a third antigen and a fourth antigen, being two different HIV Gag antigens;
- and
- (d) a fifth antigen and a sixth antigen, being two different HIV Pol antigens, and a carrier;
- wherein steps (i) and (ii) are conducted in either order, with one of the steps for priming immunization and the other step for boosting immunization.
A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject in need thereof, the method comprising administering to the subject, the method comprising
- (a) administering to the subject:
- (i) a recombinant adenovirus 26 (rAd26) vector encoding a synthetic HIV envelope protein comprising the amino acid sequence of SEQ ID NO:
- 18;
- (ii) a rAd26 vector encoding an antigen comprising the amino acid sequence of SEQ ID NO:
- 5;
- (iii) a rAd26 vector encoding an antigen comprising the amino acid sequence of SEQ ID NO:
- 28;
- and
- (iv) a rAd26 vector encoding an antigen comprising the amino acid sequence of SEQ ID NO:
- 29;
- (b) administering to the subject:
- (i) a recombinant Modified Vaccinia virus Ankara (MVA) or MVA-BN vector comprising nucleic acid encoding
- (i,a) a synthetic HIV envelope protein comprising the amino acid sequence of SEQ ID NO:
- 18;
- (i,b) a HIV Env antigen comprising the amino acid sequence of SEQ ID NO:
- 5;
- (i,c) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 28;
- (i,d) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 29.
A method of inducing an immune response against a human immunodeficiency virus (HIV) in a human subject in need thereof, the method comprising:
- (a) administering to the subject:
- (i) an recombinant Modified Vaccinia virus Ankara (MVA) or MVA-BN vector comprising nucleic acid encoding
- (i,a) a synthetic HIV envelope protein comprising the amino acid sequence of SEQ ID NO:
- 18;
- (i,b) a HIV Env antigen comprising the amino acid sequence of SEQ ID NO:
- 5;
- (i,c) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 28;
- (i,d) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 29;
- (b) administering to the subject:
- (i) an MVA or MVA-BN vector comprising nucleic acid encoding
- (i,a) a synthetic HIV envelope protein comprising the amino acid sequence of SEQ ID NO:
- 18;
- (i,b) a HIV Env antigen comprising the amino acid sequence of SEQ ID NO:
- 5;
- (i,c) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 28;
- (i,d) a HIV Gag-Pol fusion antigen comprising the amino acid sequence of SEQ ID NO:
- 29;
- and one or more of
- (ii, a) an isolated HIV gp140 protein having the sequence of amino acids 30-708 of SEQ ID NO:
- 7;
- and
- (ii, b) an isolated HIV gp140 protein having the sequence of amino acids 30-724 of SEQ ID NO:
- 36;
- and
- (iii) an aluminum phosphate adjuvant.
Dependencies are inferred from the claim text.